Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Products under Development by Stage of Development | 7 | 1 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Products under Development by Therapy Area | 8 | 1 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Products under Development by Indication | 9 | 1 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Unknown Stage Products | 12 | 1 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Products under Development by Companies | 13 | 2 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Therapeutics Assessment | 15 | 5 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 1 |
| Assessment by Molecule Type | 18 | 2 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Companies Involved in Therapeutics Development | 20 | 2 |
| APAvadis Biotechnologies Srl | 20 | 1 |
| Quantum Genomics SA | 21 | 1 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Drug Profiles | 22 | 7 |
| Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor Drug Profile | 22 | 1 |
| QGC-001 Drug Profile | 23 | 3 |
| QGC-006 Drug Profile | 26 | 1 |
| QGC-011 Drug Profile | 27 | 1 |
| QGC-101 Drug Profile | 28 | 1 |
| Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Featured News &Press Releases | 29 | 9 |
| May 17, 2016: Quantum Genomics granted two new U.S. patents covering lead product QGC001 | 29 | 1 |
| Feb 03, 2016: Quantum Genomics Expands U.S. Presence to Advance Its Development Programs for Cardiovascular Diseases | 29 | 2 |
| Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure | 31 | 1 |
| Sep 22, 2015: Quantum Genomics to meet investors at the European Large &Midcap Event, October 7 &8, 2015 | 31 | 1 |
| Mar 03, 2015: First patients recruited for Phase IIa trial of drug candidate QGC001 | 32 | 1 |
| Jan 12, 2015: Quantum Genomics at J.P. Morgan 34th annual healthcare conference | 33 | 1 |
| Dec 11, 2014: Catherine Llorens-Cortes receives the 2014 Galien France pharmaceutical research award for her work on the key role of angiotensin III at brain level in the control of blood pressure | 33 | 1 |
| Nov 17, 2014: Quantum Genomics receives all regulatory approvals to start its Phase II clinical trial in hypertension | 33 | 1 |
| Jun 18, 2014: Quantum Genomics disclosed the final results of phase I clinical trials for QGC001 during the joint Meeting of the European and International Societies of Hypertension in Athens | 34 | 1 |
| Jan 10, 2014: ANR provides a grant of 1 million for the implementation of a research program with the QGC001 | 35 | 1 |
| Dec 06, 2013: Quantum Genomics announces first results of clinical phase I studies conducted with product QGC001 | 35 | 1 |
| Oct 18, 2012: Quantum Genomics Successfully Completes Phase Ia Study Of QGC001 For Treatment Of Hypertension | 35 | 1 |
| Apr 13, 2012: Quantum Genomics Announces Initiation Of First-In-Human Clinical Study With QGC001 | 35 | 1 |
| Jan 05, 2012: Quantum Genomics Receives Approval For First Clinical Trial In Human Of QGC001 From Patients Protection Committee In France | 36 | 1 |
| Apr 01, 2011: Quantum Announces Positive Scientific Results For QGC001 In Hypertension | 37 | 1 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |
